Management of chronic prostatitis/chronic pelvic pain syndrome: A systematic review and network meta-analysis

JAMA

Volumn 305, Issue 1, 2011, Pages 78-86

  Anothaisintawee, Thunyarat ^a   Attia, John ^b,c   Nickel, J Curtis ^d   Thammakraisorn, Sangsuree ^a   Numthavaj, Pawin ^a   McEvoy, Mark ^b   Thakkinstian, Ammarin ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; BIOFLAVONOID; CELECOXIB; CIPROFLOXACIN; DOXAZOSIN; FINASTERIDE; LEVOFLOXACIN; PENTOSAN POLYSULFATE; POLLEN EXTRACT; PREDNISOLONE; PREGABALIN; ROFECOXIB; TAMSULOSIN; TERAZOSIN; TETRACYCLINE; ZAFIRLUKAST;

CHRONIC PROSTATITIS; COMPARATIVE STUDY; DRUG EFFICACY; EMBASE; HUMAN; LONGITUDINAL STUDY; MEDLINE; META ANALYSIS; MICTURITION; PAIN ASSESSMENT; PELVIS PAIN SYNDROME; PHYTOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 78650889471     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1913     Document Type: Review

References (54)

1. Roberts RO, Lieber MM, Rhodes T, et al. Prevalence of a physician-assigned diagnosis of prostatitis. Urology. 1998;51(4):578-584.
2. Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? J Urol. 1998;159(4):1224-1228.
3. de la Rosette JJ, Hubregtse MR,Meuleman EJ, et al. Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology. 1993;41(4):301-307. (Pubitemid 23111558)
4. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282(3):236-237.
5. McNaughton Collins M, Pontari MA, O'Leary MP, et al; Chronic Prostatitis Collaborative Research Network. Quality of life is impaired in menwith chronic prostatitis. J Gen Intern Med. 2001;16(10):656-662.
6. McNaughton Collins M, MacDonald R, Wilt TJ. Diagnosis and treatment of chronic abacterial prostatitis. Ann Intern Med. 2000;133(5):367-381.
7. Hetrick DC, Ciol MA, Rothman I, et al. Musculoskeletal dysfunction in men with chronic pelvic pain syndrome type III. J Urol. 2003;170(3):828-831.
8. Hochreiter WW, Nadler RB, Koch AE, et al. Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. Urology. 2000;56(6):1025-1029.
9. Nickel JC, Krieger JN, McNaughton-Collins M, et al; Chronic Prostatitis Collaborative Research Network. Alfuzosin and symptoms of chronic prostatitischronic pelvic pain syndrome. N Engl J Med. 2008;359(25):2663-2673.
10. Tuǧcu V, Taşçi AI, Fazlioǧlu A, et al. A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS). Eur Urol. 2007;51(4):1113-1117. (Pubitemid 46281417)
11. Goldmeier D, Madden P, McKenna M, Tamm N. Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. Int J STD AIDS. 2005;16(3):196-200. (Pubitemid 40469853)
12. Nickel JC, Pontari M, Moon T, et al; Rofecoxib Prostatitis Investigator Team. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol. 2003;169(4):1401-1405.
13. Elist J. Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double-blind, placebo-controlled study. Urology. 2006;67(1):60-63.
14. Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in menwith category III chronic prostatitis. Urology. 1999;54(6):960-963.
15. Wagenlehner FM, Schneider H, Ludwig M, et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome. Eur Urol. 2009;56(3):544-551.
16. Yang G, Wei Q, Li H, et al. The effect of α-adrenergic antagonists in chronic prostatitis/chronic pelvic pain syndrome. J Androl. 2006;27(6):847-852.
17. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, England: John Wiley & Sons; 2008.
18. Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et al; Chronic Prostatitis Collaborative Research Network. The National Institutes of Health Chronic Prostatitis Symptom Index. J Urol. 1999;162(2):369-375.
19. Cockett ATK, Khoury S, Aso Y, et al. Second International Consultation on Benign Prostatic Hyperplasia. Hong Kong: Scientific Communications International; 1994:624-635.
20. Krieger JN, Egan KJ, Ross SO, et al. Chronic pelvic pains represent the most prominent urogenital symptoms of "chronic prostatitis." Urology. 1996;48(5):715-721.
21. Alexander RB, Propert KJ, Schaeffer AJ, et al; Chronic Prostatitis Collaborative Research Network. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome. Ann Intern Med. 2004;141(8):581-589.
22. Bates SM, Hill VA, Anderson JB, et al. A prospective, randomized, double-blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2007;99(2):355-359.
23. Nickel JC. Treatment of chronic prostatitis/chronic pelvic pain syndrome. Int J Antimicrob Agents. 2008;31(suppl 1):S112-S116.
24. Nickel JC, Narayan P, McKay J, Doyle C. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin. J Urol. 2004;171(4):1594-1597.
25. Moreno SG, Sutton AJ, Turner EH, et al. Novel methods to deal with publication biases. BMJ. 2009;339:b2981.
26. Nüesch E, Trelle S, Reichenbach S, et al. Small study effects in meta-analyses of osteoarthritis trials. BMJ. 2010;341:c3515.
27. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105-3124. (Pubitemid 39334902)
28. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions. BMJ. 2003;326(7387):472.
29. Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol. 2008;61(5):455-463.
30. Stata [computer program]. Release 11. College Station, TX: Stata Corp; 2009.
31. Kaplan SA, Volpe MA, Te AE. A prospective, 1-year trial using saw palmetto vs finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J Urol. 2004;171(1):284-288.
32. Kulovac B, Aganović D, Prcić A, Hadziosmanović O. Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Bosn J Basic Med Sci. 2007;7(3):245-249.
33. Cheah PY, Liong ML, Yuen KH, et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome. J Urol. 2003;169(2):592-596.
34. Evliyaoǧlu Y, Burgut R. Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with α-blocking agent doxazosin; vs placebo. Int Urol Nephrol. 2002;34(3):351-356.
35. Gül O, Eroǧlu M, Ozok U. Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by Prostatitis Symptom Score Index. Int Urol Nephrol. 2001;32(3):433-436. (Pubitemid 32821210)
36. Jeong CW, Lim DJ, Son H, et al. Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urol Int. 2008;80(2):157-161.
37. Leskinen M, Lukkarinen O, Marttila T. Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome. Urology. 1999;53(3):502-505.
38. Mehik A, Alas P, Nickel JC, et al. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2003;62(3):425-429.
39. Nickel JC, Downey J, Clark J, et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome inmen. Urology. 2003;62(4):614-617.
40. Nickel JC, Downey J, Pontari MA, et al. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU Int. 2004;93(7):991-995.
41. Nickel JC, Forrest JB, Tomera K, et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome. J Urol. 2005;173(4):1252- 1255.
42. Ye ZQ, Lan RZ, Yang WM, et al. Tamsulosin treatment of chronic non-bacterial prostatitis. J Int Med Res. 2008;36(2):244-252.
43. Zhao WP, Zhang ZG, Li XD, et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (category IIIA). Braz J Med Biol Res. 2009;42(10):963-967.
44. Zhou Z, Hong L, Shen X, et al. Detection of nanobacteria infection in type III prostatitis. Urology. 2008;71(6):1091-1095.
45. Pontari MA, Krieger JN, Litwin MS, et al; Chronic Prostatitis Collaborative Research Network-2. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. Arch Intern Med. 2010;170(17):1586-1593.
46. Shoskes DA, Nickel JC, Dolinga R, Prots D. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology. 2009;73(3):538-542.
47. Nickel JC, Moon T. Chronic bacterial prostatitis. Urology. 2005;66(1):2-8.
48. Nickel JC, Xiang J. Clinical significance of non-traditional bacterial uropathogens in the management of chronic prostatitis. J Urol. 2008;179(4):1391-1395.
49. Shoskes DA, Nickel JC, Kattan MW. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2010;75(6):1249-1253.
50. Galley HF, Nelson SJ, Dubbels AM, Webster NR. Effect of ciprofloxacin on the accumulation of interleukin-6, interleukin-8, and nitrite from a human endothelial cell model of sepsis. Crit Care Med. 1997;25(8):1392-1395.
51. Yoshimura T, Kurita C, Usami E, et al. Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells. Chemotherapy. 1996;42(6):459-464.
52. Katsuno G, Takahashi HK, Iwagaki H, et al. The immunosuppressive effects of ciprofloxacin during human mixed lymphocyte reaction. Clin Immunol. 2006;119(1):110-119.
53. Nickel JC, Shoskes DA. Phenotypic approach to the management of the chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2010;106(9):1252- 1263.
54. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments. BMJ. 2005;331(7521):897-900.